Centenial Surgic (531380)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 21.80% shows topline momentum; latest quarter revenue of ₹15 Cr is meaningful relative to the ₹41 Cr market cap.
• Piotroski F-Score of 7/9 suggests improving financial health and balance-sheet discipline.
• ROCE is positive at 3.94%, so operations are not outright destroying capital.
• Book value of ₹87.16 and P/B of 1.27 provide some asset backing, though the premium needs future earnings to justify it.

Concerns

• Latest quarter net profit is ₹0 Cr and P/E is 0.00, so there is no current earnings support for the price.
• ROE is negative at -3.33%, meaning shareholders' equity is not being rewarded.
• Zero dividend yield means investors receive no cash income while waiting for a turnaround.
• Promoter holding and debt/equity data are unavailable, leaving a dangerous information gap for a microcap.

AI Analysis

At ₹110.90, Centenial Surgic is a ₹41 crore microcap in medical equipment. I like that industry, but I buy companies, not tickers. The numbers tell me this is not yet a compounding machine. Sales grew 21.80%, and the latest quarter brought ₹15 crore of revenue, yet net profit was exactly ₹0 crore. That explains the P/E of 0.00. A reported profit growth of 117.65% excites only if the base is meaningful; here, it is not. The book value stands at ₹87.16, so at ₹110.90 I am paying a 1.27 times book premium for a business whose ROE is negative at -3.33%. That is a poor trade-off. ROCE of 3.94% tells me the company earns a modest return on capital employed, but not enough to call it a wonderful operation. There is no dividend, and promoter holding and debt/equity details are unavailable—so I am flying blind on ownership and leverage. The one genuinely encouraging signal is the Piotroski F-Score of 7/9, which suggests improving fundamentals and a more solid balance sheet than the zero profit alone would imply. But a good F-Score is not a moat. The stock swung from ₹76.27 to ₹189.00 in the last year; that is Mr. Market's mood swings, not intrinsic value. Graham would ask for a margin of safety and a demonstrated ability to earn. I cannot find that in a quarter with no earnings. If this company can convert its growing sales into real profit, it could become a turnaround. Until then, I would rather wait than pay for promise.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer